You are here: Industry Insights > Astellas

News List

Amgen and Astellas to pay $125m to settle kickback charges pharmaceutical-technology
April 28, 2019
Amgen and Astellas Pharma US have agreed to pay a total of $124.75m to settle allegations that they paid kickbacks to Medicare copays for their own medications.
Seattle Genetics and Astellas Announce Positive Topline Results from Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer drugs
April 11, 2019
BOTHELL, Wash. and TOKYO, March 28, 2019 /PRNewswire/ -- Seattle Genetics, Inc.
Astellas Makes Senior-level Appointments contractpharma
April 09, 2019
Astellas Makes Senior-level Appointments
Astellas Announces Key Senior Leadership Promotions and New Hire in Medical and Development Organization firstwordpharma
April 04, 2019
Astellas is pleased to announce two recent senior-level promotions and one new hire within its Medical and Development (M&D) organization.
Xencor and Astellas Enter Collaboration for Novel Bispecific Antibody Program pharmafocusasia
April 03, 2019
Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases, today announced it has entered into a research and license agreement in...
Astellas pads Xospata's AML lead with chemo-beating survival data fiercepharma
April 02, 2019
Meanwhile, though, Astellas is examining Xospata in multiple other phase 3 trials, including those in newly diagnosed AML patients and in the post-chemo maintenance setting.
ReForm Biologics, Astellas Form Collaboration contractpharma
March 07, 2019
Will use ReForm’s technology to help progress Astellas’ biologics pipeline
Astellas and Affinivax’s novel pneumococcal vaccine enters human testing fiercepharma
February 24, 2019
About two years ago, Astellas licensed a novel pneumococcal vaccine technology from Affinivax with eyes on Pfizer’s Prevnar 13. Now, the pair has officially entered human testing.
Astellas Announces Approval in Japan for the treatment of prostate cancer, Gonax for partial changes firstwordpharma
January 09, 2019
Gonax® is a GnRH receptor antagonist with a subcutaneously injectable formulation. Astellas acquired exclusive development and commercialization rights of Gonax® for the use of prostate cancer treatment in Japan from Ferring Pharmaceuticals in January 200
Astellas, Pfizer Announce Positive Top-Line Results from Xtandi Prostate Trial americanpharmaceuticalreview
December 21, 2018
Astellas Pharma and Pfizer announced the Phase 3 ARCHES trial evaluating Xtandi (enzalutamide) plus androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC) met ....

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page